• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

80.25 +0.03 (+0.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
January 07, 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 27, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 21, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 03, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 27, 2025
Via ACCESS Newswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via AB Newswire
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
October 07, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 17, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
September 15, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
September 11, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
August 26, 2025
Via ACCESS Newswire
News headline image
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 25, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
July 21, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 30, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 26, 2025
Via ACCESS Newswire
News headline image
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
June 01, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 21, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 09, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Award
April 16, 2025
Via ACCESS Newswire
News headline image
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 18, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 10, 2025
Via ACCESS Newswire
News headline image
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 08, 2025
Via ACCESS Newswire
News headline image
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 03, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 29, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap